This clinical trial tests the effectiveness of an online weight loss plus resistance training intervention (iLIVE) to decrease obesity and improve frailty in men with prostate cancer who received androgen deprivation therapy (ADT). Androgen deprivation therapy increases the risk of frailty, weight gain and obesity in prostate cancer survivors. The combination of frailty and obesity can lead to a decrease in quality of life and an increased risk of recurrent falls. Using iLIVE may improve obesity and frailty in men with prostate cancer who receive ADT.
INTERVENTION PARTICIPANTS: Age 18 or older
INTERVENTION PARTICIPANTS: Diagnosed with histologically confirmed prostate cancer
INTERVENTION PARTICIPANTS: Received >= 6 months of ADT any time in the past 10 years
INTERVENTION PARTICIPANTS: Completed radiotherapy, chemotherapy and/or surgery > 6 weeks prior to
INTERVENTION PARTICIPANTS: Unintentional weight loss > 5% within the last year
INTERVENTION PARTICIPANTS: Contraindication to moderate intensity exercise
INTERVENTION PARTICIPANTS: Health or medical condition that affects weight status/body composition (e.g., Cushing's syndrome, uncontrolled hyper-/hypo- thyroidism)
INTERVENTION PARTICIPANTS: Active malignancy (other than non-melanoma skin cancer)
OHSU Knight Cancer Institute
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Oregon Health and Science University
Collaborator
University of Alabama at Birmingham
Collaborator